Navigation Links
Mylan Receives FDA Approval for Generic Version of Prostate Cancer Treatment Casodex(R)
Date:7/7/2009

PITTSBURGH, July 7 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Bicalutamide Tablets, 50 mg.

Bicalutamide Tablets are the generic version of AstraZeneca's prostate cancer treatment Casodex(R), which had total U.S. sales of approximately $322 million for the 12 months ending March 31 for the same strength, according to IMS Health. Mylan has begun to ship this product.

Currently, Mylan has 118 ANDAs pending FDA approval representing $82.8 billion in annual brand sales, according to IMS Health. Thirty-five of these pending ANDAs are potential first-to-file opportunities, representing $16.7 billion in annual brand sales, according to IMS Health.

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generics and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest -- and highest quality -- product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. For more information, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Mylan Announces Strategic Collaboration with Biocon to Enter the Global Generic Biologics Market
2. Mylan Again Calls for an End to Authorized Generics During 180-Day Exclusivity Period
3. Mylan Receives Tentative FDA Approval for Generic Version of Singulair(R)
4. Mylans Matrix Selected by the Clinton HIV/AIDS Initiative and UNITAID as the Primary Supplier of Five Second-Line and Seven Pediatric HIV/AIDS Treatments
5. Mylans Matrix Receives First Tentative FDA Approval Under PEPFAR for Generic Truvada(R)
6. Mylan Confirms Four First-to-File Challenges
7. Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent
8. Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008
9. Shire Receives FOSRENOL Paragraph IV Notice Letters from Barr Laboratories and Mylan
10. Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
11. Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2017)... ... October 06, 2017 , ... ... and applications consulting for microscopy and surface analysis, Nanoscience Instruments is now ... Analytical offers a broad range of contract analysis services for advanced applications. ...
(Date:10/7/2017)... 6, 2017  The 2017 Nobel Prize in ... Jacques Dubochet, Joachim Frank and ... cryo-electron microscopy (cryo-EM) have helped to broaden ... biology community. The winners worked with systems manufactured ... produce highly resolved, three-dimensional images of protein structures ...
(Date:10/6/2017)... ... October 06, 2017 , ... On Tuesday, October ... on INSIGhT, the first-ever adaptive clinical trial for glioblastoma (GBM). The featured speaker ... is free and open to the public, but registration is required. , WHAT: ...
(Date:10/5/2017)... ... 2017 , ... Understanding the microbiome, the millions of bacteria that live in ... Are My Future, the newest exhibit on display at the University City Science Center’s ... through the lens of the gut microbiome. , Gut Love opens October 12, ...
Breaking Biology Technology:
(Date:4/6/2017)... LONDON , April 6, 2017 ... Control, RFID, ANPR, Document Readers, by End-Use (Transportation & ... Energy Facility, Oil, Gas & Fossil Generation Facility, Nuclear ... Healthcare, Educational, Other) Are you looking for ... Authentication sector? ...
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
(Date:3/28/2017)... India , March 28, 2017 ... IP, Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), Software ... Vertical, and Region - Global Forecast to 2022", published ... Billion in 2016 and is projected to reach USD ... between 2017 and 2022. The base year considered for ...
Breaking Biology News(10 mins):